112
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Prognostic Nomogram for Overall Survival of Patients Aged 50 Years or Older with Cervical Cancer

ORCID Icon, , &
Pages 7741-7754 | Published online: 06 Nov 2021

References

  • alys-Tagoe BNL, Aheto JMK, Mensah G, Biritwum RB, Yawson AE. Cervical cancer screening practices among women in Ghana: evidence from wave 2 of the WHO study on global AGEing and adult health. BMC Women's Health. 2020;20(1):49. doi:10.1186/s12905-020-00915-9.
  • de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180–e190. doi:10.1016/S2214-109X(19)30488-7.
  • Moore KN, Java JJ, Slaughter KN, et al. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol. 2016;143(2):294–301. doi:10.1016/j.ygyno.2016.08.317.
  • Polterauer S, Grimm C, Hofstetter G, et al. Nomogram prediction for overall survival of patients diagnosed with cervical cancer. Br J Cancer. 2012;107(6):918–924. doi:10.1038/bjc.2012.340.
  • Chen CC, Wang L, Lin JC, Jan JS. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy. J Formos Med Assoc. 2015;114(3):231–237. doi:10.1016/j.jfma.2012.10.021.
  • Winer I, Alvarado-Cabrero I, Hassan O, et al. The prognostic significance of histologic type in early stage cervical cancer - A multi-institutional study. Gynecol Oncol. 2015;137(3):474–478. doi:10.1016/j.ygyno.2015.02.005.
  • Cui L, Shi Y, Zhang GN. Perineural invasion as a prognostic factor for cervical cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2015;292(1):13–19. doi:10.1007/s00404-015-3627-z.
  • Ouyang D, Yang P, Cai J, Sun S, Wang Z. Comprehensive analysis of prognostic alternative splicing signature in cervical cancer. Cancer Cell Int. 2020;20:221. doi:10.1186/s12935-020-01299-4.
  • Yang J, Tian G, Pan Z, et al. Nomograms for predicting the survival rate for cervical cancer patients who undergo radiation therapy: a SEER analysis. Future Oncol. 2019;15(26):3033–3045. doi:10.2217/fon-2019-0029.
  • Wang T, Gao T, Yang J, et al. Preoperative prediction of pelvic lymph nodes metastasis in early-stage cervical cancer using radiomics nomogram developed based on T2-weighted MRI and diffusion-weighted imaging. Eur J Radiol. 2019;114:128–135. doi:10.1016/j.ejrad.2019.01.003
  • Kong TW, Kim J, Son JH, et al. Preoperative nomogram for prediction of microscopic parametrial infiltration in patients with FIGO stage IB cervical cancer treated with radical hysterectomy. Gynecol Oncol. 2016;142(1):109–114. doi:10.1016/j.ygyno.2016.05.010
  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
  • Kaneko N. Factors associated with cervical cancer screening among young unmarried Japanese women: results from an internet-based survey. BMC Women’s Health. 2018;18(1):132.
  • Chang C, Chen J, Chang WY, Chiang AJ. Tumor size has a time-varying effect on recurrence in cervical cancer. J Low Genit Tract Dis. 2016;20(4):317–320. doi:10.1097/LGT.0000000000000238
  • Wang J, Wang T, Yang YY, Chai YL, Shi F, Liu ZI. Patient age, tumor appearance and tumor size are risk factors for early recurrence of cervical cancer. Mol Clin Oncol. 2015;3(2):363–366. doi:10.3892/mco.2014.465
  • Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010;116(1):44–49. doi:10.1016/j.ygyno.2009.09.006
  • Zhou J, Zhang WW, Wu SG, et al. The impact of examined lymph node count on survival in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Cancer Manag Res. 2017;9:315–322. doi:10.2147/CMAR.S141335
  • Fleming ND, Frumovitz M, Schmeler KM, et al. Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol. 2015;136(1):48–53. doi:10.1016/j.ygyno.2014.11.010.
  • Koh WJ, Greer BE, Abu-Rustum NR, et al. Cervical cancer, version 2.2015. J Natl Compr Canc Netw. 2015;13(4):395–404; quiz 404. doi:10.6004/jnccn.2015.0055.
  • Huang K, Jia M, Li P, et al. Radiotherapy improves the survival of patients with metastatic cervical cancer: a propensity-matched analysis of SEER database. Int J Gynecol Cancer. 2018;28(7):1360–1368. doi:10.1097/IGC.0000000000001313.
  • Jhawar S, Hathout L, Elshaikh MA, Beriwal S, Small W Jr, Mahmoud O. Adjuvant chemoradiation therapy for cervical cancer and effect of timing and duration on treatment outcome. Int J Radiat Oncol Biol Phys. 2017;98(5):1132–1141. doi:10.1016/j.ijrobp.2017.03.045
  • Frumovitz M, Querleu D, Gil-Moreno A, et al. Lymphadenectomy in locally advanced cervical cancer study (LiLACS): Phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2-IVA cervical cancer. J Minim Invasive Gynecol. 2014;21(1):3–8. doi:10.1016/j.jmig.2013.07.007
  • Xie Y, Zhao FH, Lu SH, et al. Assessment of quality of life for the patients with cervical cancer at different clinical stages. Chin J Cancer. 2013;32(5):275–282. doi:10.5732/cjc.012.10047